A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide^™, a PEGylated peptidic erythropoiesis-stimulating agent

References

• Agoram, B., Aoki, K., Doshi, S., Gegg, C., Jang, G., Molineus, G., et al. (2009). Investigation of the effects of altered receptor-binding activity on the clearance of erythropoiesis-stimulation proteins: nonerythropoietin receptor-mediated pathways may play a role. J Pharm Sci 98:2198–2211.
   PubMed Web of Science ®Google Scholar
• Bozzini, C. E., Barrio Rendo, M. E., Devoto, F. C., Epper, C. E. (1970). Studies on medullary and extramedullary erythropoiesis in the adult mouse. Am J Physiol 219:724–728.
   PubMed Web of Science ®Google Scholar
• Calcieti, P., Veronese, F. M. (2003). Pharmacokinetic and biodistribution properties of poly(ethyleneglycol)–protein conjugates. Adv Drug Del Rev 55:1261–1277.
   PubMed Web of Science ®Google Scholar
• Davies, B., Morris, T. (1993). Physiological parameter in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., Lykos, M. A. (2003). Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290–299.
   PubMed Web of Science ®Google Scholar
• Fan, Q., Leuther, K. L., Holmes, C. P., Fong, K-L., Zhang, J., Velkovska, S., et al. (2006). Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent for the treatment of anemia. Exp Hematol 34:1303–1311.
   PubMed Web of Science ®Google Scholar
• Fishbane, S. (2008). Anemia and cardiovascular risk in the patient with kidney disease. Heart Failure Clin 4:401–410.
   PubMedGoogle Scholar
• Fisher, J. W. (2003). Erythropoietin: physiology and pharmacology update. Exp Biol Med 228:1–14.
   PubMed Web of Science ®Google Scholar
• Greaves, P. (2000). Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. New York: Elsevier Science.
   Google Scholar
• Macdougall, I., Geronemus, R., Ardelean, L., Pergola, P., DeSilva, V., Zeig, S., et al. (2008). Interim evaluation of long-term safety and tolerability of Hematide during maintenance treatment of anemia in patients with chronic kidney disease on hemodialysis and not on hemodialysis. J Am Soc Nephrol 19:278A.
   Google Scholar
• Moore, D. M. (2000). Hematology of the mouse (Mus musculus). In: Feldman, B. F., Zinkl, J. G., Jain, N. C. (Eds.), Schalm’s Veterinary Hematology (pp 1219–1224). Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins.
   Google Scholar
• Rossert, J., Casadevall, N., Eckardt, K. (2004) Antierythropoietin antibodies and pure red cell aplasia. J. Am Soc Nephrol 15:398–406.
   PubMed Web of Science ®Google Scholar
• Singh, A. K., Milford, E., Fishbane, S., Keithi-Reddy, S. R. (2008). Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int 74:679–683.
   PubMed Web of Science ®Google Scholar
• Stead, R. B., Lambert, J., Wessels, D., Iwashita, J. S., Leuther, K. K., Woodburn, K. W., et al. (2006). Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in a healthy volunteer. Blood 108:1830–1834.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. (2001). FDA toxicology review of darbepoetin alfa, BLA 99–1492, Amgen, Inc., approved September 17, 2001. Available at: Website accessed on Feb 2, 2008, from http://www.fda.gov/cder/biologics/products/darbamg091701.htm. Accessed February 2, 2008.
   Google Scholar
• Villeval, J-L, Metcalf, D., Johnson, G. R. (1992). Fatal polycythemia induced in mice by dysregulated erythropoietin production by hematopoietic cells. Leukemia 6:107–115.
   PubMed Web of Science ®Google Scholar
• Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., et al. (2007). PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35:9–16.
   PubMed Web of Science ®Google Scholar
• Woodburn, K. W., Fan, Q., Winslow, S., Chen, M-J., Mortensen, R. B., Casadevall, N., et al. (2007). Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 35:1201–1208.
   PubMed Web of Science ®Google Scholar
• Woodburn, K. W., Schatz, P. J., Fong, K-L., Wilson, S. D., Ferrell, T., Spainhour, C. B., et al. (2008a). Preclinical safety and pharmacology of Hematide™, a peptidic erythropoiesis-stimulating agent (ESA), in rats and monkeys. Drug Chem Tox 31:229–244.
   PubMed Web of Science ®Google Scholar
• Woodburn, K. W., Wilson, S. D., Fong, K. L, Schatz, P. J., Ferrell, T., Spainhour, C. B., et al. (2008b). Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis-stimulating agent in monkeys. Haematologica 93:1376–1379.
   PubMed Web of Science ®Google Scholar
• Woodburn, K. W., Wilson, S. D., Fong, K-L., Schatz, P. J, Spainhour, C. B., Norton, D. (2009). Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Basic Clin Pharmacol Toxicol 104:155–163.
   PubMed Web of Science ®Google Scholar